Seyed Hamidreza Mahmoudpour1,2,3, Folkert W Asselbergs4,5,6,7, Patrick C Souverein1, Anthonius de Boer1, Anke H Maitland-van der Zee1,8. 1. Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands. 2. Institute for Medical Biostatistics, Epidemiology, and Informatics (IMBEI), Department of Biometry and Bioinformatics, University Medical Centre of the Johannes Gutenberg University, Mainz, Germany. 3. Center for Thrombosis and Hemostasis (CTH), University Medical Centre of the Johannes Gutenberg University, Mainz, Germany. 4. Department of Cardiology, Division Heart & Lungs, University Medical Center Utrecht, University of Utrecht, the Netherlands. 5. Durrer Center for Cardiovascular Research, Netherlands Heart Institute, Utrecht, the Netherlands. 6. Institute of Cardiovascular Science, Faculty of Population Health Sciences, University College London, London, UK. 7. Farr Institute of Health Informatics Research and Institute of Health Informatics, University College London, London, UK. 8. Department of Respiratory Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands.
Abstract
AIM: Angiotensin-converting enzyme inhibitors (ACEIs) are widely prescribed for several cardiovascular indications. This study investigated patterns of ACEI use for various indications. METHODS: A descriptive, retrospective population-based study was conducted using data from the UK Clinical Practice Research Datalink. Patients starting ACEIs (2007-2014) were selected and ACEI indications were retrieved from electronically recorded medical records. Stratified by indication, we distinguished between persistent and nonpersistent ACEI use, considering a 6-month interval between two prescription periods as a maximum for persistent use. Five-year persistence rates for various indications were calculated using the Kaplan-Meier method and compared in a log-rank test. Nonpersistent users were subdivided into three groups: (i) stop; (ii) restart; and (iii) switch to an angiotensin II-receptor blocker. Patients who received ACEIs for hypertension who switched to other classes of antihypertensive medications were further investigated. RESULTS: In total, 254 002 ACEI initiators were identified with hypertension (57.6%), myocardial infarction (MI; 4.2%), renal disease (RD; 3.7%), heart failure (HF; 1.5%), combinations of the above (17.2%) or none of the above (15.8%). Five-year persistence rates ranged from 43.2% (RD) to 68.2% (MI; P < 0.0001). RD and HF patients used ACEIs for the shortest time (average 23.6 and 25.0 months, respectively). For the nonpersistent group, the percentage of switchers to angiotensin II-receptor blockers ranged from 27.6% (RD) to 42.2% (MI) and the restarters ranged from 15.0% (HF) to 18.1% (group without indication). CONCLUSIONS: Depending on the indication, there are various rates of ACEI nonpersistence. Patients with RD are most likely to discontinue treatment.
AIM: Angiotensin-converting enzyme inhibitors (ACEIs) are widely prescribed for several cardiovascular indications. This study investigated patterns of ACEI use for various indications. METHODS: A descriptive, retrospective population-based study was conducted using data from the UK Clinical Practice Research Datalink. Patients starting ACEIs (2007-2014) were selected and ACEI indications were retrieved from electronically recorded medical records. Stratified by indication, we distinguished between persistent and nonpersistent ACEI use, considering a 6-month interval between two prescription periods as a maximum for persistent use. Five-year persistence rates for various indications were calculated using the Kaplan-Meier method and compared in a log-rank test. Nonpersistent users were subdivided into three groups: (i) stop; (ii) restart; and (iii) switch to an angiotensin II-receptor blocker. Patients who received ACEIs for hypertension who switched to other classes of antihypertensive medications were further investigated. RESULTS: In total, 254 002 ACEI initiators were identified with hypertension (57.6%), myocardial infarction (MI; 4.2%), renal disease (RD; 3.7%), heart failure (HF; 1.5%), combinations of the above (17.2%) or none of the above (15.8%). Five-year persistence rates ranged from 43.2% (RD) to 68.2% (MI; P < 0.0001). RD and HF patients used ACEIs for the shortest time (average 23.6 and 25.0 months, respectively). For the nonpersistent group, the percentage of switchers to angiotensin II-receptor blockers ranged from 27.6% (RD) to 42.2% (MI) and the restarters ranged from 15.0% (HF) to 18.1% (group without indication). CONCLUSIONS: Depending on the indication, there are various rates of ACEI nonpersistence. Patients with RD are most likely to discontinue treatment.
Authors: Thomas A Burke; Miriam C Sturkenboom; Shou-en Lu; Charles E Wentworth; Yong Lin; George G Rhoads Journal: J Hypertens Date: 2006-06 Impact factor: 4.844
Authors: Stephen Ph Alexander; Doriano Fabbro; Eamonn Kelly; Neil V Marrion; John A Peters; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies Journal: Br J Pharmacol Date: 2017-12 Impact factor: 8.739
Authors: Carla A Sueta; Jo E Rodgers; Patricia P Chang; Lei Zhou; Emily M Thudium; Anna M Kucharska-Newton; Sally C Stearns Journal: Am J Cardiol Date: 2015-05-08 Impact factor: 2.778
Authors: Stefan Koudstaal; Mar Pujades-Rodriguez; Spiros Denaxas; Johannes M I H Gho; Anoop D Shah; Ning Yu; Riyaz S Patel; Chris P Gale; Arno W Hoes; John G Cleland; Folkert W Asselbergs; Harry Hemingway Journal: Eur J Heart Fail Date: 2016-12-23 Impact factor: 15.534
Authors: Yao Qiao; Jung-Im Shin; Yingying Sang; Lesley A Inker; Alex Secora; Shengyuan Luo; Josef Coresh; G Caleb Alexander; John W Jackson; Alex R Chang; Morgan E Grams Journal: Mayo Clin Proc Date: 2019-10-13 Impact factor: 7.616
Authors: Seyed Hamidreza Mahmoudpour; Folkert W Asselbergs; Patrick C Souverein; Anthonius de Boer; Anke H Maitland-van der Zee Journal: Br J Clin Pharmacol Date: 2018-07-24 Impact factor: 4.335
Authors: Tórur Sjúrðarson; Jacob Bejder; Andreas Breenfeldt Andersen; Thomas Bonne; Kasper Kyhl; Tóra Róin; Poula Patursson; Noomi Oddmarsdóttir Gregersen; May-Britt Skoradal; Michael Schliemann; Malte Lindegaard; Pál Weihe; Magni Mohr; Nikolai B Nordsborg Journal: Physiol Rep Date: 2022-07
Authors: Tórur Sjúrðarson; Jacob Bejder; Andreas Breenfeldt Andersen; Thomas C Bonne; Kasper Kyhl; Martin Thomassen; Júlia Prats; Noomi Oddmarsdóttir Gregersen; May-Britt Skoradal; Pál Weihe; Nikolai B Nordsborg; Magni Mohr Journal: Eur J Appl Physiol Date: 2022-10-22 Impact factor: 3.346
Authors: James Yarmolinsky; Virginia Díez-Obrero; Tom G Richardson; Marie Pigeyre; Jennifer Sjaarda; Guillaume Paré; Venexia M Walker; Emma E Vincent; Vanessa Y Tan; Mireia Obón-Santacana; Demetrius Albanes; Jochen Hampe; Andrea Gsur; Heather Hampel; Rish K Pai; Mark Jenkins; Steven Gallinger; Graham Casey; Wei Zheng; Christopher I Amos; George Davey Smith; Richard M Martin; Victor Moreno Journal: PLoS Med Date: 2022-02-03 Impact factor: 11.069
Authors: Sara Malo; Isabel Aguilar-Palacio; Cristina Feja; María Jesús Lallana; Javier Armesto; María José Rabanaque Journal: PLoS One Date: 2021-01-15 Impact factor: 3.240